Hepatitis B immune globulin

被引：19
作者：
Habib, Shahid
Shaikh, Obaid S.
机构：
[1] Iowa Hlth Des Moines, Ctr Liver Dis, Des Moines, IA USA
[2] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Sch Med, Pittsburgh, PA USA
来源：
DRUGS OF TODAY | 2007年 / 43卷 / 06期
关键词：
D O I：
10.1358/dot.2007.43.6.1050792
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hepatitis B immune globulin (HBIG) is a purified solution of human immunoglobulin that has high titers of antibody to hepatitis B surface antigen (anti-HBs). It is derived from plasma donated by individuals immune to hepatitis 6 viral infection. HBIG is widely administered to confer passive prophylactic immunity against the hepatitis B virus because of the ability of anti-HBs to neutralize hepatitis B virions. However, it is not indicated for the treatment of acute or chronic hepatitis B. The use of HBIG is recommended in the following clinical situations: i) Acute exposure to blood and secretions containing hepatitis B surface antigen (HBsAg); ii) sexual contact with HBsAg-positive persons; iii) household exposure to persons with acute hepatitis B; iv) perinatal exposure of infants born to HBsAg-positive mothers; v) liver transplantation. (c) 2007 Prous Science. All rights reserved.
引用
收藏
页码：379 / 394
页数：16
相关论文
共 84 条
[1]   Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure [J].
Abdelmalek, MF ;
Pasha, TM ;
Zein, NN ;
Persing, DH ;
Wiesner, RH ;
Douglas, DD .
LIVER TRANSPLANTATION, 2003, 9 (12) :1253-1257
[2]   Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation [J].
Adler, R ;
Safadi, R ;
Caraco, Y ;
Rowe, M ;
Etzioni, A ;
Ashur, Y ;
Shouval, D .
HEPATOLOGY, 1999, 29 (04) :1299-1305
[3]   REVIEW - PROTECTIVE EFFICACY OF HEPATITIS-B VACCINES IN NEONATES [J].
ANDRE, FE ;
ZUCKERMAN, AJ .
JOURNAL OF MEDICAL VIROLOGY, 1994, 44 (02) :144-151
[4]  
BEASLEY RP, 1983, HEPATOLOGY, V3, P135
[5]  
BEASLEY RP, 1978, VIRAL HEPATITIS, P333
[6]  
Carman WF, 1996, HEPATOLOGY, V24, P489, DOI 10.1053/jhep.1996.v24.pm0008781312
[7]  
CDC, 2001, Morbidity and Mortality Weekly Report, V50, P1
[8]  
*CDC, 1997, MMWR-MORBID MORTAL W, V46, P378
[9]   OCCULT HEPATITIS-B VIRUS AS SOURCE OF INFECTION IN LIVER-TRANSPLANT RECIPIENTS [J].
CHAZOUILLERES, O ;
MAMISH, D ;
KIM, M ;
CAREY, K ;
FERRELL, L ;
ROBERTS, JP ;
ASCHER, NL ;
WRIGHT, TL .
LANCET, 1994, 343 (8890) :142-146
[10]   Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors [J].
Chen, YS ;
Wang, CC ;
de Villa, VH ;
Wang, SH ;
Cheng, YF ;
Huang, TL ;
Jawan, B ;
Chiu, KW ;
Chen, CL .
CLINICAL TRANSPLANTATION, 2002, 16 (06) :405-409
123456789